Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial.

Humar A, Hadjiyannis Y, Macedo C, Tran LM, Elinoff BD, Hughes CB, Ganesh SR, Zahorchak AF, Ables EM, Styn MA, Landsittel D, Zeevi A, Lakkis FG, Metes DM, Thomson AW

Open source

DOI
10.1038/s41467-026-71280-8
Published
2026 Apr 17
Container
Nature communications
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-71280-8,
  title = {Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial.},
  author = {Humar A and Hadjiyannis Y and Macedo C and Tran LM and Elinoff BD and Hughes CB and Ganesh SR and Zahorchak AF and Ables EM and Styn MA and Landsittel D and Zeevi A and Lakkis FG and Metes DM and Thomson AW},
  year = {2026},
  journal = {Nature communications},
  doi = {10.1038/s41467-026-71280-8},
  url = {https://doi.org/10.1038/s41467-026-71280-8}
}

RIS

TY  - JOUR
TI  - Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial.
AU  - Humar A
AU  - Hadjiyannis Y
AU  - Macedo C
AU  - Tran LM
AU  - Elinoff BD
AU  - Hughes CB
AU  - Ganesh SR
AU  - Zahorchak AF
AU  - Ables EM
AU  - Styn MA
AU  - Landsittel D
AU  - Zeevi A
AU  - Lakkis FG
AU  - Metes DM
AU  - Thomson AW
PY  - 2026
JO  - Nature communications
DO  - 10.1038/s41467-026-71280-8
UR  - https://doi.org/10.1038/s41467-026-71280-8
ER  - 

APA

A, H., Y, H., C, M., LM, T., BD, E., CB, H., SR, G., AF, Z., EM, A., MA, S., D, L., A, Z., FG, L., DM, M., & AW, T. (2026). Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial.. Nature communications. https://doi.org/10.1038/s41467-026-71280-8

Source records